FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

FDA Clears Teleflex Perfusion Balloon Catheter

FDA clears a Teleflex 510(k) for its Ringer Perfusion Balloon Catheter for use in percutaneous transluminal coronary angioplasty procedures.

latest-news-card-1
Federal Register

Psychopharmacologic Drugs Panel Renewal

Federal Register notice: FDA renews its Psychopharmacologic Drugs Advisory Committee for an additional two years beyond the charter expiration date.

latest-news-card-1
Human Drugs

FDA Explains New LabelComp Tool

FDA says its new LabelComp artificial intelligence tool automates the identification of adverse event changes in drug labeling updates.

latest-news-card-1
Human Drugs

FDA OKs Expanded Jemperli Indication

FDA approves an sBLA expanding the endometrial cancer indication for GlaxoSmithKlines Jemperli.

latest-news-card-1
Human Drugs

Abbott Device Correction on FreeStyle Libre 3

Abbott issues a medical device correction for a small number of FreeStyle Libre 3 sensors because they may provide incorrect high glucose readings.

latest-news-card-1
Human Drugs

Novartis Sues FDA to Reverse Generic Entresto OK

Novartis files a lawsuit against FDA that seeks to reverse the agencys recent approval of MSN Laboratories generic version of Novartiss Entresto (sacu...

latest-news-card-1
Human Drugs

Telix Pharma Hit with Refuse-to-File on BLA

FDA sends Telix Pharmaceuticals a refuse-to-file letter on its BLA for TLX250-CDx (89Zr-DFO-girentuximab), an investigational imaging agent for clear ...

latest-news-card-1
Human Drugs

Man Indicted for Selling Counterfeit Cancer Drugs

The Justice Department says a resident of India has been indicted on federal charges of trafficking in fake cancer drugs sold in the U.S.

latest-news-card-1
Human Drugs

New Quantitative Medicine CoE Resources

The CDER Quantitative Medicine Center of Excellence posts four new resources.

latest-news-card-1
Federal Register

Biosimilar User Fee Rates For FY 2025

Federal Register notice: FDA set biosimilar user fee rates for fiscal year 2025.